An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

Inclusion Criteria: * End stage renal disease patients on dialysis for at least 90 days deemed to be at low risk by the investigator for being hospitalized or have concurrent infections * Serum phosphorous level \> 5 mg/dl * Stable phosphate binder regimen for 2 week prior to enrollment * Stable dose of Vitamin D for 4 weeks prior to enrollment * Stable calcimimetic dose for 4 week prior to enrollment Exclusion Criteria: * patients who are pregnant * patients who have pre existing thrombocytopenia defined as a platelet count of \<100 x 109/L * abnormal LFTs * baseline CRP \> 15 g/dl * known sensitivity to any of the active ingredients * patients who are currently enrolled in a clinical trial, or who have been in a clinical trial in the last six months * are currently taking any immunosuppressive medications